Eversana Life Sciences Services, LL Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Eversana Life Sciences Services, LL Pharmaceutical Import Records from India — 3 Products, $1.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Eversana Life Sciences Services, LL — Pharmaceutical Importer Profile (2026) | 3 Products, $1.7M Trade | TransData Nexus

Eversana Life Sciences Services, LL

Pharmaceutical Importer · United States · Diabetes & Endocrine Focus · $1.7M Total Trade · DGFT Verified

Eversana Life Sciences Services, LL is a pharmaceutical importer based in United States with a total trade value of $1.7M across 3 products in 3 therapeutic categories. Based on 71 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Eversana Life Sciences Services, LL sources from 3 verified Indian suppliers, with Intas Pharmaceuticals Limited accounting for 99.6% of imports.

Eversana Life Sciences Services, LL — Import Portfolio & Supplier Network

Eversana Life Sciences Services, LL import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Eversana Life Sciences Services, LL?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$61.5M	1,908	99.6%
Rubicon Research Private Limited	$204.3K	31	0.3%
Aizant Drug Research Solutions Private Limited	$50.0K

What Formulations Does Eversana Life Sciences Services, LL Import?

Formulation	Value	Ships
Pharmaceutical drugs and medicine-	$1.4M	32
Pharma drugs & medi tacrolimus cap 1 MG	$1.3M	30
Phr drugs&medi bupropion TAB USP 300 MG	$937.6K	22
Pharma drugs & medi olmesartan	$887.0K	26
Pharmaceutical drugs and medicine	$814.8K	33
Pharma drugs & medi letrozole TAB USP 2.	$766.6K	25
Pharma drugs & medi levothyroxine 100mcg	$700.7K	19
Phr drugs&medi naltrexone hcl TAB USP	$700.0K	14
Phr drugs&medi bupropion TAB USP 150 MG	$696.7K	17
Pharmaceutical drugs and medicine-	$696.5K	14
Pharma drugs & medi levothyroxine 75 MCG	$580.2K	15
Pharmaceutical drugs and medicine-	$545.4K	14
Pharma drugs & medi diltiazem hcl er	$542.4K	14
Pharma drugs & medi buspiron hcl TAB	$542.2K	18
Pharma drugs & medi eplerenone 25 MG	$530.0K	13

Eversana Life Sciences Services, LL imports 558 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Levothyroxine	Diabetes & Endocrine	$1.6M	60	2.0%	11
2	Clonazepam	CNS & Psychiatric	$103.5K	9	0.1%	16
3	Busulfan	Advanced Oncology	$80.4K	2	1.6%	11

Eversana Life Sciences Services, LL imports 3 pharmaceutical products across 3 categories into United States totaling $1.7M.

Eversana Life Sciences Services, LL — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Eversana Life Science Services, LLC is a leading independent provider of global services to the life sciences industry, specializing in the commercialization of pharmaceuticals and healthcare products. Established in 2018 and headquartered in Chicago, Illinois, the company offers a comprehensive suite of integrated solutions that span all stages of the product lifecycle, delivering sustainable value for patients, prescribers, channel partners, and payers.

The company's services encompass market access, product launch support, patient services, and integrated compliance, among others. Eversana serves over 670 organizations, including both innovative start-ups and established pharmaceutical companies, aiming to advance life sciences solutions for a healthier world.

2Distribution Network

Eversana Life Science Services, LLC operates a robust distribution network across the United States, with facilities in Memphis, Tennessee, and Mason, Ohio. The Memphis location, situated at 4580 S Mendenhall Road, serves as a significant hub for the company's logistics and distribution operations. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's extensive network and partnerships suggest a well-established infrastructure capable of supporting nationwide distribution.

3Industry Role

In the United States pharmaceutical supply chain, Eversana Life Science Services, LLC functions primarily as a logistics intermediary and distributor. The company imports finished pharmaceutical formulations from various global suppliers, including India, and manages the distribution of these products to various stakeholders within the healthcare system. This role positions Eversana as a critical link between international manufacturers and the U.S. market, facilitating the availability of diverse pharmaceutical products to meet patient needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Eversana Life Sciences Services, LL

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Eversana Life Science Services, LLC demonstrates a high degree of supplier concentration in its sourcing strategy. The company's total import value from India amounts to $1.7 million USD, with 71 shipments covering three therapeutic categories. The top three products imported are Levothyroxine ($1.6 million, 2.0% share), Clonazepam ($103,000, 0.1% share), and Busulfan ($80,000, 1.6% share). Notably, Levothyroxine accounts for a substantial portion of the total import value, indicating a strategic focus on this product.

The supplier base is highly concentrated, with three verified Indian suppliers: INTAS Pharmaceuticals Limited ($61.5 million, 99.6% share), Rubicon Research Private Limited ($204,000, 0.3% share), and Aizant Drug Research Solutions Private Limited ($50,000, 0.1% share). This concentration suggests a strategic choice to maintain strong, stable relationships with a select group of suppliers, potentially ensuring consistent product quality and supply reliability.

2Supply Chain Resilience

Eversana Life Science Services, LLC's supply chain exhibits a degree of resilience through its diversified sourcing strategy. The company imports a total of 558 unique formulations from India, indicating a broad product portfolio that can mitigate risks associated with dependency on a limited number of products. However, the heavy reliance on INTAS Pharmaceuticals Limited, which accounts for 99.6% of the import value, introduces potential vulnerabilities. Any disruptions with this supplier could significantly impact the company's supply chain.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets standards for drug safety, efficacy, and quality. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and ensuring that imported drugs meet U.S. standards.

The marketing authorization pathway for Indian generics involves several steps:

1. Abbreviated New Drug Application (ANDA): Indian manufacturers must submit an ANDA to the FDA, demonstrating that their generic product is bioequivalent to the reference listed drug.

2. Good Manufacturing Practice (GMP) Compliance: Manufacturers must comply with FDA's GMP regulations, ensuring that products are consistently produced and controlled.

3. FDA Inspection: The FDA may conduct inspections of manufacturing facilities to verify compliance with GMP standards.

4. Approval and Importation: Upon approval, the generic product can be imported and marketed in the U.S.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are governed by the FDA. Indian exporters must ensure that their products are approved through the ANDA process and comply with FDA's GMP regulations. Recognition of GMP certificates from other jurisdictions, such as EU GMP, WHO GMP, or PIC/S, can facilitate the approval process, but the FDA may still require additional inspections or documentation.

Eversana Life Sciences Services, LL — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Eversana Life Science Services, LLC's product category focus is primarily on the Diabetes & Endocrine therapeutic area, which constitutes 89.4% of their imports. This emphasis suggests a strategic alignment with prevalent health conditions and market demand for endocrine therapies. The inclusion of CNS & Psychiatric (6.0%) and Advanced Oncology (4.6%) categories indicates a diversified approach to address a range of therapeutic needs.

Market demand for these imports is driven by the high prevalence of endocrine disorders, mental health conditions, and cancer, necessitating a steady supply of effective treatments. Eversana's focus on these areas positions them to meet critical healthcare needs and capitalize on substantial market opportunities.

2Sourcing Profile

Eversana Life Science Services, LLC's generic drug sourcing strategy involves importing finished pharmaceutical formulations from India, with a particular emphasis on products like Levothyroxine. The company's portfolio includes 558 unique formulations, indicating a broad and diverse product range. India's role as a key supplier aligns with its status as a major global producer of generic pharmaceuticals, offering cost-effective and high-quality products.

3Market Positioning

Frequently Asked Questions — Eversana Life Sciences Services, LL

What products does Eversana Life Sciences Services, LL import from India?

Eversana Life Sciences Services, LL imports 3 pharmaceutical products across 3 categories. Top imports: Levothyroxine ($1.6M), Clonazepam ($103.5K), Busulfan ($80.4K).

Who supplies pharmaceuticals to Eversana Life Sciences Services, LL from India?

Eversana Life Sciences Services, LL sources from 3 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (99.6% of imports, $61.5M).

What is Eversana Life Sciences Services, LL's total pharmaceutical import value?

Eversana Life Sciences Services, LL's total pharmaceutical import value from India is $1.7M, based on 71 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Eversana Life Sciences Services, LL focus on?

Eversana Life Sciences Services, LL imports across 3 categories. The largest: Diabetes & Endocrine (89.4%), CNS & Psychiatric (6.0%), Advanced Oncology (4.6%).

Get Full Eversana Life Sciences Services, LL Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.